Pfizer

4,080.25
+45.35
(1.12%)
Market Cap
18,666.22 Cr
EPS
120.51
PE Ratio
29.99
Dividend Yield
0.87 %
Industry
Healthcare
52 Week High
6,451.15
52 Week Low
3,701.00
PB Ratio
4.92
Debt to Equity
0.01
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from3 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+66.67 %
+66.67 %
Hold
Hold+33.33 %
+33.33 %
Sell
Sell0.0 %
0.0 %
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,687.55
#1 4,04,899.77
33.61
#1 49,887.20
12.06
#1 9,648
13.77
47.60
5,589.30
1,48,378.35
69.15
8,184.00
0.89
1,600
#1 64.53
47.92
1,463.05
1,18,158.10
22.92
26,520.70
14.17
4,155
47.38
50.89
3,129.00
1,05,899.58
56.83
10,785.70
11.59
1,656
13.54
45.29
2,350.50
96,976.58
46.77
10,615.60
19.57
1,942
-16.38
48.68
1,109.50
92,582.82
#1 17.01
28,905.40
12.36
5,578
1.69
40.66
1,969.25
89,904.33
30.58
20,141.50
#1 19.94
1,936
38.82
46.62
868.85
87,426.64
18.74
19,831.50
13.82
3,831
29.92
44.56
29,641.10
62,985.27
46.40
6,097.20
10.80
1,201
16.01
48.36
1,082.45
62,868.87
17.41
29,559.20
17.55
3,169
-10.04
41.61
Growth Rate
Revenue Growth
-6.02 %
Net Income Growth
-11.64 %
Cash Flow Change
-27.79 %
ROE
-21.18 %
ROCE
-17.45 %
EBITDA Margin (Avg.)
-4.58 %

Yearly Financial Results

Annual Financials
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
Revenue
1,921
2,103
2,067
2,083
2,249
2,336
2,320
2,674
2,526
2,374
2,439
Expenses
1,470
1,586
1,617
1,468
1,516
1,579
1,526
1,775
1,616
1,558
1,534
EBITDA
450
517
450
615
733
757
793
898
910
816
905
Operating Profit %
21 %
21 %
18 %
25 %
27 %
27 %
32 %
32 %
33 %
29 %
31 %
Depreciation
131
124
63
66
71
103
109
115
106
62
58
Interest
1
1
1
0
1
11
15
11
13
15
13
Profit Before Tax
238
402
517
548
660
643
669
773
824
746
834
Tax
138
179
180
188
231
133
171
160
200
195
214
Net Profit
100
223
337
360
429
509
498
613
624
551
616
EPS in ₹
15.26
66.66
73.61
78.70
93.78
111.28
108.77
133.89
136.38
120.51
134.50

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
2,612
2,914
3,261
3,690
3,940
4,405
3,266
3,901
4,001
4,229
Fixed Assets
944
895
902
950
886
973
894
869
749
713
Current Assets
1,253
1,630
2,051
2,417
2,715
3,048
1,925
2,397
2,493
2,738
Capital Work in Progress
13
3
15
1
0
1
3
1
8
0
Investments
0
4
0
0
0
0
0
0
0
0
Other Assets
1,655
2,011
2,343
2,739
3,054
3,432
2,369
3,030
3,244
3,516
Total Liabilities
2,612
2,914
3,261
3,690
3,940
4,405
3,266
3,901
4,001
4,229
Current Liabilities
606
759
780
954
892
873
774
853
657
547
Non Current Liabilities
32
36
62
52
37
137
99
183
136
87
Total Equity
1,973
2,118
2,419
2,683
3,011
3,396
2,393
2,864
3,207
3,596
Reserve & Surplus
1,927
2,072
2,373
2,637
2,966
3,350
2,347
2,819
3,162
3,550
Share Capital
46
46
46
46
46
46
46
46
46
46

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
181
-417
-4
-17
23
1,690
-1,613
-88
-26
75
Investing Activities
68
-701
-250
-238
35
1,530
-469
-575
-36
54
Operating Activities
114
346
329
332
98
323
427
667
356
257
Financing Activities
-1
-62
-83
-110
-110
-164
-1,571
-181
-346
-235

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
63.92 %
63.92 %
63.92 %
63.92 %
63.92 %
63.92 %
63.92 %
63.92 %
63.92 %
63.92 %
63.92 %
63.92 %
63.92 %
63.92 %
63.92 %
63.92 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
2.82 %
0.00 %
3.33 %
3.22 %
3.54 %
2.75 %
DIIs
13.08 %
8.98 %
8.98 %
8.84 %
8.57 %
7.91 %
14.85 %
14.93 %
14.89 %
14.89 %
15.01 %
15.15 %
15.33 %
15.84 %
16.03 %
16.79 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
15.03 %
14.11 %
14.11 %
14.25 %
14.19 %
14.08 %
13.94 %
13.71 %
13.70 %
13.69 %
13.61 %
13.21 %
12.90 %
12.55 %
12.15 %
12.12 %
Others
7.97 %
12.98 %
12.98 %
12.99 %
13.32 %
14.08 %
7.29 %
7.43 %
7.49 %
7.50 %
4.64 %
7.72 %
4.52 %
4.46 %
4.35 %
4.41 %
No of Share Holders
1,45,980
1,21,153
1,21,153
1,26,808
1,25,287
1,23,449
1,22,028
1,17,950
1,17,194
1,15,988
1,16,948
1,12,456
1,09,214
1,06,098
98,824
1,05,015

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 20 20 22.5 330 35 35 70 35 0.00
Dividend Yield (%) 0.00 0.92 0.6 0.56 7.29 0.8 1 1.67 0.87 0.00

Corporate Action

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 20183 days ago
Announcement under Regulation 30 (LODR)-Change in ManagementApr 01, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementApr 01, 2025
Closure of Trading WindowMar 31, 2025
Update On Transfer And Assignment Of PfizerS Unexpired Leasehold Rights In The Land Situated At Plot No. 16 Trans Thane Creek Industrial Area Turbhe Thane And Sale Of Structures And Buildings Constructed Thereon To Zoetis Pharmaceutical Research Private Mar 29, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 19, 2025
Board Meeting Outcome for Marketing And Supply Agreement With Mylan Pharmaceuticals Private LimitedFeb 21, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateFeb 14, 2025
Receipt Of GST Order Levying Tax Demand And PenaltyFeb 05, 2025
Receipt Of GST Order Levying Tax Demand And PenaltyFeb 05, 2025
Receipt Of GST Order For A Tax Demand Interest And PenaltyFeb 04, 2025
Levy Of Tax Demand And PenaltyFeb 03, 2025
Integrated Filing (Financial)Feb 01, 2025
Update On Transfer And Assignment Of PfizerS Unexpired Leasehold Rights In The Land Situated At Plot No. 16 Trans Thane Creek Industrial Area Turbhe Thane To Zoetis Pharmaceutical Research Private LimFeb 01, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJan 31, 2025
Board Meeting Outcome for Outcome Of The Board Meeting- Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024Jan 31, 2025
Board Meeting Intimation for Board Meeting To Consider And Take On Record The Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024Jan 24, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 14, 2025
Closure of Trading WindowDec 30, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 17, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 11, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 03, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 19, 2024
Announcement under Regulation 30 (LODR)-Change in ManagementNov 14, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 12, 2024
Announcement under Regulation 30 (LODR)-Change in DirectorateNov 10, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 07, 2024
Announcement under Regulation 30 (LODR)-Change in ManagementNov 05, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 05, 2024
Statement Of Related Party Transactions For The Half Year Ended September 30, 2024Oct 28, 2024
Board Meeting Outcome for Outcome Of The Board Meeting-Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024Oct 28, 2024
Board Meeting Intimation for To Consider And Take On Record The Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024.Oct 21, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateOct 16, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateOct 08, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 08, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateOct 02, 2024
Closure of Trading WindowSep 30, 2024
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.Aug 31, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportAug 29, 2024
Shareholder Meeting / Postal Ballot-Outcome of AGMAug 28, 2024
Intimation Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.Aug 14, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 08, 2024
Intimation Of Revised Record Date.Aug 07, 2024
Business Responsibility and Sustainability Reporting (BRSR)Aug 06, 2024
Annual General Meeting And Record Date NoticeAug 06, 2024
Annual General Meeting And Record Date NoticeAug 06, 2024
Reg. 34 (1) Annual Report.Aug 06, 2024
Intimation Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015Jul 31, 2024
Announcement under Regulation 30 (LODR)-Change in DirectorateJul 29, 2024
Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended June 30, 2024.Jul 29, 2024

Technical Indicators

RSI(14)
Neutral
49.47
ATR(14)
Less Volatile
127.37
STOCH(9,6)
Neutral
58.62
STOCH RSI(14)
Overbought
98.83
MACD(12,26)
Bullish
13.81
ADX(14)
Weak Trend
13.07
UO(9)
Bearish
61.52
ROC(12)
Downtrend And Accelerating
-0.43
WillR(14)
Neutral
-23.04

About Pfizer

Pfizer Limited is an Indian pharmaceutical company engaged in manufacturing, marketing, trading, and exporting pharmaceutical products. It has a manufacturing facility in Goa and works with contract manufacturers across India. The company offers a diverse portfolio of products including vaccines, anti-infectives, cardiac medications, pain relief, maternal nutrition, gastrointestinal treatments, contraceptives, anti-inflammatories, and respiratory medicines. Pfizer's key focus areas include vaccines, with Prevenar 13 for pneumococcal prevention, and inflammation and immunology treatments for chronic immune system diseases. The company has undergone several mergers, acquisitions, and divestments over the years, including the merger with Wyeth Limited in 2014 and the sale of certain established medicine brands to Mylan Pharmaceuticals in 2022.
Chairperson NamePradip P Shah